Table 2.
Treatment characteristics of re-irradiation for recurrent or second primary H&N cancer
| Variable | Median (Range) | |
|---|---|---|
| Time between 1st and 2nd radiotherapy | 17 months (4–176 months) | |
| Initial radiation dose, EQD2 (α/β = 10) | 68.0 Gy (30.8 Gy – 72.0 Gy) | |
| Re-irradiation dose, EQD2 (α/β = 10) | 58.4 Gy (3.7 Gy – 66.0 Gy) | |
| Re-irradiation dose for RT completion group, EQD2 (α/β = 10) | 58.4 Gy (30.1 Gy – 66.0 Gy) | |
| Re-irradiation dose for the RT non-completion group, EQD2 (α/β = 10) | 27.45 Gy (3.7 Gy – 47.8 Gy) | |
| Intended re-irradiation dose for the non-completion group, EQD2 (α/β = 10) | 58.4 Gy (49.6 Gy − 66.0 Gy) | |
| Cumulative radiation dose, EQD2 (α/β = 10) | 122.8 Gy (63.7 Gy – 132.0 Gy) | |
| Cumulative radiation dose for the boost-group, EQD2 (α/β = 10) | 124.0 Gy (89.2 Gy – 132.0 Gy) | |
| Cumulative radiation dose for the no boost-group, EQD2 (α/β = 10) | 119.1 Gy (63.7 Gy – 131.6 Gy) | |
| PTV | 105.1 cm3 (16.7 cm3–905.3 cm3) | |
| Cumulative Dmaxspinal cord, EQD2 (α/β = 3) | 41.0 Gy (9.9 Gy – 74.8 Gy) | |
| n | % | |
| Radiotherapy | ||
| definitive | 31 | 64.6 |
| adjuvant | 17 | 35.4 |
| Completion radiotherapy | ||
| no | 6 | 12.5 |
| yes | 42 | 87.5 |
| Boost | ||
| no boost | 33 | 68.8 |
| integrated boost | 10 | 20.8 |
| sequential boost | 5 | 10.4 |
| Simultaneous chemotherapy | ||
| no | 20 | 41.7 |
| yes | 28 | 58.3 |
| Chemotherapy,n = 28 | ||
| cetuximab | 17 | 60.7 |
| cisplatin | 8 | 28.6 |
| cisplatin/5-fluorouracil | 1 | 3.6 |
| cisplatin/cetuximab | 1 | 3.6 |
| carboplatin | 1 | 3.6 |